Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALIMERA SCIENCES INCALIM · Entity 11664 | Chief Financial Officer & SVP | November 21, 2023 | November 28, 2023 |
| Lineage Cell Therapeutics, Inc.BTX · Entity 6045 | Chief Financial Officer | December 18, 2018 | December 20, 2018 |
| Processa Pharmaceuticals, Inc.PCSA · Entity 8210 | Chief Financial Officer | July 26, 2026 | July 29, 2026 |
| ROCKWELL MEDICAL, INC.RMTI · Entity 7426 | See Remarks | September 09, 2022 | September 13, 2022 |
| Serina Therapeutics, Inc.AGE · Entity 9581 | Chief Financial Officer | December 31, 2018 | February 15, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALIMERA SCIENCES INC
Report date November 21, 2023 · Filed November 28, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.38 · Expires 2033-11-21 | Direct | 50,000 |
Reported balance
After 2023-11-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-11-21 · Grant · Acquired 50,000 · Balance 50,000 F1: The employee stock option shall vest as follows: one-fourth of the shares shall vest on November 21, 2024, with the remaining shares vesting in 36 equal monthly installments beginning on December 21, 2024, subject to reporting person's continuous employment. |
| Common StockSEC Table I · non-derivative | Direct | 75,500 |
Reported balance
Holding disclosure · report date 2023-11-21 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 75,500 |
Filing footnotes · ownership attribution and instrument terms
F1: The employee stock option shall vest as follows: one-fourth of the shares shall vest on November 21, 2024, with the remaining shares vesting in 36 equal monthly installments beginning on December 21, 2024, subject to reporting person's continuous employment.
Lineage Cell Therapeutics, Inc.
Report date December 18, 2018 · Filed December 20, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Shares, no par valueSEC Table I · non-derivative | Direct | 24,078 |
Last balance in matching sequence
After 2018-12-18 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2018-12-18 · Exercise / conversion · Acquired 22,500 · Balance 31,859 F1: Shares earned by the Reporting Person as a result of the vesting of Restrictive Stock Units ("RSUs") granted to the Reporting Person on May 24, 2018. F2: Does not include RSUs payable in shares of the Issuer's common stock that have not vested as of the date of this Report and shares that may be acquired upon the exercise of certain stock options. Row 2 · 2018-12-18 · Tax withholding · Disposed 7,781 · Balance 24,078 F3: Securities withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 22,500 RSUs, the grant of which was previously reported on a Form 8-K. F2: Does not include RSUs payable in shares of the Issuer's common stock that have not vested as of the date of this Report and shares that may be acquired upon the exercise of certain stock options. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 11,250 |
Reported balance
After 2018-12-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-12-18 · Exercise / conversion · Disposed 22,500 · Balance 11,250 F4: 25% of the RSUs granted on May 24, 2018 vested on October 4, 2018, 50% of the RSUs vested on December 18, 2018, then the remaining 25% of the RSUs shall vest based on the sole determination by the Board of Directors that BioTime has achieved certain milestones, subject to the continuing employment of the Reporting Person on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person upon vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares earned by the Reporting Person as a result of the vesting of Restrictive Stock Units ("RSUs") granted to the Reporting Person on May 24, 2018.
F2: Does not include RSUs payable in shares of the Issuer's common stock that have not vested as of the date of this Report and shares that may be acquired upon the exercise of certain stock options.
F3: Securities withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 22,500 RSUs, the grant of which was previously reported on a Form 8-K.
F4: 25% of the RSUs granted on May 24, 2018 vested on October 4, 2018, 50% of the RSUs vested on December 18, 2018, then the remaining 25% of the RSUs shall vest based on the sole determination by the Board of Directors that BioTime has achieved certain milestones, subject to the continuing employment of the Reporting Person on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person upon vesting.
Processa Pharmaceuticals, Inc.
Report date July 26, 2026 · Filed July 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 17,323 |
Reported balance
After 2026-07-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-26 · Grant · Acquired 11,883 · Balance 17,323 F1: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death. F3: Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025. |
| Common StockSEC Table I · non-derivative | Direct | 16,689 |
Reported balance
Holding disclosure · report date 2026-07-26 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 16,689 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.96 | Direct | 12,960 |
Reported balance
Holding disclosure · report date 2026-07-26 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 12,960 F2: Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years. F3: Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death.
F2: Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years.
F3: Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025.
ROCKWELL MEDICAL, INC.
Report date September 09, 2022 · Filed September 13, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.66 · Expires 2032-09-09 | Direct | 80,000 |
Reported balance
After 2022-09-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-09-09 · Grant · Acquired 80,000 · Balance 80,000 F1: Stock options vest in four equal installments on the first, second, third and fourth anniversaries of September 9, 2022, subject to the Reporting Person's continued employment with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock options vest in four equal installments on the first, second, third and fourth anniversaries of September 9, 2022, subject to the Reporting Person's continued employment with the Issuer.
Serina Therapeutics, Inc.
Report date December 31, 2018 · Filed February 15, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | Direct | 935 |
Reported balance
Holding disclosure · report date 2018-12-31 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 935 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 26, 2026 Filed Jul 29, 2026 00:29 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 11,883 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-26-001558 · form4.xml · derivative · entry 2 SKIBSTED RUSSELL · CIK 0001308105 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,323 Underlying: Common Stock · 11,883 shares Expires not disclosed F1 · shares: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death. F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death. F3 · balance_after: Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 20:17 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 3,277 | $1.93 | $6,324.61 |
DisclosureSEC source: 0000897069-26-001478 · form4.xml · nonDerivative · entry 1 SKIBSTED RUSSELL · CIK 0001308105 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,689 Read SEC document |
| June 15, 2026 Filed Jun 16, 2026 20:23 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 2,654 | $2.22 | $5,891.88 |
DisclosureSEC source: 0000897069-26-001412 · form4.xml · nonDerivative · entry 1 SKIBSTED RUSSELL · CIK 0001308105 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,412 Read SEC document |
| May 29, 2026 Filed Jun 1, 2026 20:59 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 2,292 | $2.57 | $5,890.44 |
DisclosureSEC source: 0000897069-26-001293 · form4.xml · nonDerivative · entry 1 SKIBSTED RUSSELL · CIK 0001308105 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,758 Read SEC document |
| May 15, 2026 Filed May 19, 2026 21:35 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 1,984 | $2.97 | $5,892.48 |
DisclosureSEC source: 0000897069-26-001171 · form4.xml · nonDerivative · entry 1 SKIBSTED RUSSELL · CIK 0001308105 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,466 F1 · balance_after: Shares adjusted to correct immaterial errors made on the Form 4 filed on May 1, 2026. The corrected price per share for the purchase made on April 30, 2026 is $2.71, not $2.69, which reduces the amount purchased on April 30, 2026 by 16 shares. Read SEC document |
| April 30, 2026 Filed May 1, 2026 20:38 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 2,190 | $2.69 | $5,891.10 |
DisclosureSEC source: 0000897069-26-001008 · form4.xml · nonDerivative · entry 1 SKIBSTED RUSSELL · CIK 0001308105 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,498 Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 20:49 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 1,984 | $2.97 | $5,892.48 |
DisclosureSEC source: 0000897069-26-000902 · form4.xml · nonDerivative · entry 1 SKIBSTED RUSSELL · CIK 0001308105 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,308 Read SEC document |
| March 31, 2026 Filed Apr 1, 2026 21:18 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 2,324 | $2.54 | $5,891.34 |
DisclosureSEC source: 0000897069-26-000754 · form4.xml · nonDerivative · entry 1 SKIBSTED RUSSELL · CIK 0001308105 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,324 Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 20:27 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantStock Options (Right to Buy) · Derivative | 324,000 | $0.00 Strike: $0.20 | $0.00 |
DisclosureSEC source: 0000897069-25-001547 · form4.xml · derivative · entry 2 SKIBSTED RUSSELL · CIK 0001308105 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 324,000 Underlying: Common Stock · 324,000 shares Expires not disclosed F2 · derivative.exercise_date: Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years. F2 · derivative.expiration_date: Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 20:27 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 108,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-25-001547 · form4.xml · derivative · entry 1 SKIBSTED RUSSELL · CIK 0001308105 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,000 Underlying: Common Stock · 108,000 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on October 1, 2026, and one-thirty-sixth each month thereafter until fully vested on October 1, 2028. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on October 1, 2026, and one-thirty-sixth each month thereafter until fully vested on October 1, 2028. Read SEC document |
| July 24, 2025 Filed Jul 28, 2025 20:30 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 1,775,044 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-25-001217 · form4.xml · derivative · entry 1 SKIBSTED RUSSELL · CIK 0001308105 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,803,044 Underlying: Common Stock · 1,775,044 shares Expires not disclosed F1 · shares: Restricted stock granted under the Processa Pharmaceuticals, Inc. 2019 Omnibus Incentive Plan ("Omnibus Plan"), of which 1,753,212 shares are subject to stockholder approval of the revised Omnibus Plan. F2 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2026, and one-thirty-sixth each month thereafter until fully vested on January 1, 2028. F2 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2026, and one-thirty-sixth each month thereafter until fully vested on January 1, 2028. Read SEC document |
| July 16, 2024 Filed Jul 18, 2024 20:46 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 28,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-24-001518 · form4.xml · derivative · entry 1 SKIBSTED RUSSELL · CIK 0001308105 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires not disclosed F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting of 50% on 7/16/25 and the remainder upon achievement of certain criteria. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting of 50% on 7/16/25 and the remainder upon achievement of certain criteria. Read SEC document |
| November 21, 2023 Filed Nov 28, 2023 16:02 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | GrantEmployee Stock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $3.38 | $0.00 |
DisclosureSEC source: 0001104659-23-121644 · tm2331668-3_4seq1.xml · derivative · entry 2 SKIBSTED RUSSELL · CIK 0001308105 · Chief Financial Officer & SVP 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2033-11-21 F1 · derivative.exercise_date: The employee stock option shall vest as follows: one-fourth of the shares shall vest on November 21, 2024, with the remaining shares vesting in 36 equal monthly installments beginning on December 21, 2024, subject to reporting person's continuous employment. Read SEC document |
| March 26, 2023 Filed Mar 28, 2023 19:23 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | GrantCommon Stock | 58,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-009832 · doc4.xml · nonDerivative · entry 1 SKIBSTED RUSSELL · CIK 0001308105 · Chief Financial Officer & SVP 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,500 F1 · shares: The Reporting Person was awarded 58,000 shares of restricted common stock in connection with his service as an executive officer of the Issuer, which shares vest in four equal annual installments beginning March 26, 2023, so long as the Reporting Person's service as an employee of the Issuer is continuous from the Grant Date through the applicable anniversary thereof. Read SEC document |
| January 09, 2023 Filed Jan 10, 2023 16:29 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | GrantEmployee Stock Option (Right to Buy) · Derivative | 52,500 | $0.00 Strike: $2.82 | $0.00 |
DisclosureSEC source: 0001474506-23-000019 · primary_doc.xml · derivative · entry 2 SKIBSTED RUSSELL · CIK 0001308105 · Chief Financial Officer & SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,500 Underlying: Common Stock · 52,500 shares Expires 2033-01-08 F2 · derivative.exercise_date: Becomes exercisable: (a) with respect to 13,125 options, when the Reporting Person completes 12 months of continuous service with the Issuer, and (b) with respect to the remaining 39,375 options, in equal monthly installments over 36 months beginning one month after the vesting commencement date of January 9, 2024, so long as the Reporting Person's service as an employee of the Issuer is continuous from the Grant Date through the applicable vesting date. Read SEC document |
| January 09, 2023 Filed Jan 10, 2023 16:29 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | GrantCommon Stock | 17,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001474506-23-000019 · primary_doc.xml · nonDerivative · entry 1 SKIBSTED RUSSELL · CIK 0001308105 · Chief Financial Officer & SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 F1 · shares: The Reporting Person was awarded 17,500 shares of restricted common stock in connection with his service as an executive officer of the Issuer, which shares vest in four equal annual installments beginning January 9, 2024, so long as the Reporting Person's service as an employee of the Issuer is continuous from the Grant Date through the applicable anniversary thereof. Read SEC document |
| September 09, 2022 Filed Sep 13, 2022 20:30 UTC | ROCKWELL MEDICAL, INC. RMTI · Entity 7426 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $1.66 | $0.00 |
DisclosureSEC source: 0001104659-22-099655 · tm2225800-1_4seq1.xml · derivative · entry 1 SKIBSTED RUSSELL · CIK 0001308105 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2032-09-09 F1 · derivative.exercise_date: Stock options vest in four equal installments on the first, second, third and fourth anniversaries of September 9, 2022, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 01:35 UTC | ROCKWELL MEDICAL, INC. RMTI · Entity 7426 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0001628280-20-013684 · wf-form4_160030648779893.xml · derivative · entry 2 SKIBSTED RUSSELL · CIK 0001308105 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2030-09-15 F2 · derivative.exercise_date: Stock options vest upon achievement of specified milestone events. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 01:35 UTC | ROCKWELL MEDICAL, INC. RMTI · Entity 7426 | GrantStock Option (Right to Buy) · Derivative | 600,000 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0001628280-20-013684 · wf-form4_160030648779893.xml · derivative · entry 1 SKIBSTED RUSSELL · CIK 0001308105 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2030-09-15 F1 · derivative.exercise_date: Stock options vest in three equal installments on the first, second and third anniversaries of September 15, 2020. Read SEC document |
| December 18, 2018 Filed Dec 20, 2018 13:40 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | Exercise / conversionRestricted Stock Units · Derivative | 22,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-063604 · doc4.xml · derivative · entry 3 SKIBSTED RUSSELL · CIK 0001308105 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 Underlying: Common Shares · 22,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the RSUs granted on May 24, 2018 vested on October 4, 2018, 50% of the RSUs vested on December 18, 2018, then the remaining 25% of the RSUs shall vest based on the sole determination by the Board of Directors that BioTime has achieved certain milestones, subject to the continuing employment of the Reporting Person on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person upon vesting. F4 · derivative.expiration_date: 25% of the RSUs granted on May 24, 2018 vested on October 4, 2018, 50% of the RSUs vested on December 18, 2018, then the remaining 25% of the RSUs shall vest based on the sole determination by the Board of Directors that BioTime has achieved certain milestones, subject to the continuing employment of the Reporting Person on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person upon vesting. Read SEC document |
| December 18, 2018 Filed Dec 20, 2018 13:40 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | Tax withholdingCommon Shares, no par value | 7,781 | $1.03 | $8,014.43 |
DisclosureSEC source: 0001209191-18-063604 · doc4.xml · nonDerivative · entry 2 SKIBSTED RUSSELL · CIK 0001308105 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,078 F3 · shares: Securities withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 22,500 RSUs, the grant of which was previously reported on a Form 8-K. F2 · balance_after: Does not include RSUs payable in shares of the Issuer's common stock that have not vested as of the date of this Report and shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| December 18, 2018 Filed Dec 20, 2018 13:40 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | Exercise / conversionCommon Shares, no par value | 22,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-063604 · doc4.xml · nonDerivative · entry 1 SKIBSTED RUSSELL · CIK 0001308105 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,859 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares earned by the Reporting Person as a result of the vesting of Restrictive Stock Units ("RSUs") granted to the Reporting Person on May 24, 2018. F2 · balance_after: Does not include RSUs payable in shares of the Issuer's common stock that have not vested as of the date of this Report and shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| October 04, 2018 Filed Oct 9, 2018 23:18 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | Exercise / conversionRestricted Stock Units · Derivative | 11,250 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-054606 · doc4.xml · derivative · entry 3 SKIBSTED RUSSELL · CIK 0001308105 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,750 Underlying: Common Shares · 11,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the RSUs granted on May 24, 2018 vested on October 4, 2018, then the remaining 75% of the RSUs shall vest based on the sole determination by the Board of Directors that BioTime has achieved certain milestones, subject to the continuing employment of the Reporting Person on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person upon vesting. F4 · derivative.expiration_date: 25% of the RSUs granted on May 24, 2018 vested on October 4, 2018, then the remaining 75% of the RSUs shall vest based on the sole determination by the Board of Directors that BioTime has achieved certain milestones, subject to the continuing employment of the Reporting Person on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person upon vesting. Read SEC document |
| October 04, 2018 Filed Oct 9, 2018 23:18 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | Tax withholdingCommon Shares, no par value | 3,891 | $2.22 | $8,638.02 |
DisclosureSEC source: 0001209191-18-054606 · doc4.xml · nonDerivative · entry 2 SKIBSTED RUSSELL · CIK 0001308105 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,359 F3 · shares: Securities withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 11,250 RSUs, the grant of which was previously reported on a Form 8-K. F2 · balance_after: Does not include RSUs payable in shares of the Issuer's common stock that have not vested as of the date of this Report and shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| October 04, 2018 Filed Oct 9, 2018 23:18 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | Exercise / conversionCommon Shares, no par value | 11,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-054606 · doc4.xml · nonDerivative · entry 1 SKIBSTED RUSSELL · CIK 0001308105 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares earned by the Reporting Person as a result of the vesting of Restrictive Stock Units ("RSUs") granted to the Reporting Person on May 24, 2018. F2 · balance_after: Does not include RSUs payable in shares of the Issuer's common stock that have not vested as of the date of this Report and shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| March 15, 2018 Filed Mar 19, 2018 23:05 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | GrantOption to Purchase Common Shares · Derivative | 150,000 | $0.00 Strike: $2.54 | $0.00 |
DisclosureSEC source: 0001209191-18-020726 · doc4.xml · derivative · entry 2 SKIBSTED RUSSELL · CIK 0001308105 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Shares · 150,000 shares Expires 2028-03-14 F2 · derivative.exercise_date: One quarter of the options shall vest upon the completion of continuous service from the date of grant until February 1, 2019, and the balance of the options shall vest in 36 equal monthly installments, commencing on February 1, 2019, based upon continued service. Read SEC document |
| August 23, 2017 Filed Aug 25, 2017 20:33 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | PurchaseCommon Shares, no par value | 2,000 | $2.64 | $5,284.80 |
DisclosureSEC source: 0001209191-17-050305 · doc4.xml · nonDerivative · entry 1 SKIBSTED RUSSELL · CIK 0001308105 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · price: The purchase price per share represents a weighted average of prices ranging from $2.6373 to $2.6475 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Does not include shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 21:18 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | GrantOption to Purchase Common Shares · Derivative | 250,000 | $0.00 Strike: $3.16 | $0.00 |
DisclosureSEC source: 0001209191-17-038605 · doc4.xml · derivative · entry 1 SKIBSTED RUSSELL · CIK 0001308105 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Shares · 250,000 shares Expires 2027-06-05 F1 · derivative.exercise_date: One quarter of the options shall vest upon the completion of continuous service from the date of grant until February 1, 2018, and the balance of the options shall vest in 36 equal monthly installments, commencing on February 1, 2018, based upon continued service. Read SEC document |
| September 08, 2016 Filed Sep 10, 2016 01:06 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | GrantOption to Purchase Common Shares · Derivative | 50,000 | $0.00 Strike: $3.49 | $0.00 |
DisclosureSEC source: 0001209191-16-140853 · doc4.xml · derivative · entry 1 SKIBSTED RUSSELL · CIK 0001308105 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Shares · 50,000 shares Expires 2026-09-07 F1 · derivative.exercise_date: One quarter of the options shall vest upon the completion of 12 months of continuous employment from the date of grant on September 8, 2016 and the balance shall vest in 36 monthly installments upon the completion of each month of continuous employment from the first anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.